Literature DB >> 1689394

Naturally occurring human parainfluenza type 3 viruses exhibit divergence in amino acid sequence of their fusion protein neutralization epitopes and cleavage sites.

K V Coelingh1, C C Winter.   

Abstract

Many human parainfluenza type 3 virus (PIV3) strains isolated from children with respiratory illness are resistant to neutralization by monoclonal antibodies (MAbs) which recognize epitopes in antigenic site A or B of the fusion (F) protein of the prototype 1957 PIV3 strain. The F protein genes of seven PIV3 clinical isolates were sequenced to determine whether their neutralization-resistant phenotypes were associated with specific differences in amino acids which are recognized by neutralizing MAbs. Several clinical strains which were resistant to neutralization by site A or B MAbs had amino acid differences at residues 398 or 73, respectively. These specific changes undoubtedly account for the neutralization-resistant phenotype of these isolates, since identical substitutions at residues 398 or 73 in MAb-selected escape mutants confer resistance to neutralization by site A or B MAbs. The existence of identical changes in naturally occurring and MAb-selected neutralization-resistant PIV3 strains raises the possibility that antigenically different strains may arise by immune selection during replication in partially immune children. Three of the seven clinical strains examined had differences in their F protein cleavage site sequence. Whereas the prototype PIV3 strain has the cleavage site sequence Arg-Thr-Lys-Arg, one clinical isolate had the sequence Arg-Thr-Arg-Arg and two isolates had the sequence Arg-Thr-Glu-Arg. The different cleavage site sequences of these viruses did not affect their level of replication in either continuous simian or bovine kidney cell monolayers (in the presence or absence of exogenous trypsin or plasmin) or in the upper or lower respiratory tract of rhesus monkeys. We conclude that two nonconsecutive basic residues within the F protein cleavage site are sufficient for efficient replication of human PIV3 in primates.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1689394      PMCID: PMC249251     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  26 in total

1.  Newly recognized myxoviruses from children with respiratory disease.

Authors:  R M CHANOCK; R H PARROTT; K COOK; B E ANDREWS; J A BELL; T REICHELDERFER; A Z KAPIKIAN; F M MASTROTA; R J HUEBNER
Journal:  N Engl J Med       Date:  1958-01-30       Impact factor: 91.245

2.  Antigenic and structural properties of the hemagglutinin-neuraminidase glycoprotein of human parainfluenza virus type 3: sequence analysis of variants selected with monoclonal antibodies which inhibit infectivity, hemagglutination, and neuraminidase activities.

Authors:  K L van Wyke Coelingh; C C Winter; E D Jorgensen; B R Murphy
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

3.  Characterization of a pantropic variant of Sendai virus derived from a host range mutant.

Authors:  M Tashiro; E Pritzer; M A Khoshnan; M Yamakawa; K Kuroda; H D Klenk; R Rott; J T Seto
Journal:  Virology       Date:  1988-08       Impact factor: 3.616

4.  Single amino acid substitution of Sendai virus at the cleavage site of the fusion protein confers trypsin resistance.

Authors:  M Itoh; H Shibuta; M Homma
Journal:  J Gen Virol       Date:  1987-11       Impact factor: 3.891

5.  Nucleotide and deduced amino acid sequence of hemagglutinin-neuraminidase genes of human type 3 parainfluenza viruses isolated from 1957 to 1983.

Authors:  K L van Wyke Coelingh; C C Winter; B R Murphy
Journal:  Virology       Date:  1988-01       Impact factor: 3.616

6.  Fusion glycoprotein of human parainfluenza virus type 3: nucleotide sequence of the gene, direct identification of the cleavage-activation site, and comparison with other paramyxoviruses.

Authors:  M K Spriggs; R A Olmsted; S Venkatesan; J E Coligan; P L Collins
Journal:  Virology       Date:  1986-07-15       Impact factor: 3.616

7.  Protease activation mutants of Sendai virus: sequence analysis of the mRNA of the fusion protein (F) gene and direct identification of the cleavage-activation site.

Authors:  M C Hsu; A Scheid; P W Choppin
Journal:  Virology       Date:  1987-01       Impact factor: 3.616

8.  Identification of biological activities of paramyxovirus glycoproteins. Activation of cell fusion, hemolysis, and infectivity of proteolytic cleavage of an inactive precursor protein of Sendai virus.

Authors:  A Scheid; P W Choppin
Journal:  Virology       Date:  1974-02       Impact factor: 3.616

9.  Molecular cloning and sequence determination of the fusion protein gene of human parainfluenza virus type 1.

Authors:  J R Merson; R A Hull; M K Estes; J A Kasel
Journal:  Virology       Date:  1988-11       Impact factor: 3.616

10.  Attenuation of bovine parainfluenza virus type 3 in nonhuman primates and its ability to confer immunity to human parainfluenza virus type 3 challenge.

Authors:  K L van Wyke Coelingh; C C Winter; E L Tierney; W T London; B R Murphy
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

View more
  17 in total

1.  Complete sequence of the genome of avian paramyxovirus type 2 (strain Yucaipa) and comparison with other paramyxoviruses.

Authors:  Madhuri Subbiah; Sa Xiao; Peter L Collins; Siba K Samal
Journal:  Virus Res       Date:  2008-06-20       Impact factor: 3.303

2.  Two distinct human parainfluenza virus type 1 genotypes detected during the 1991 Milwaukee epidemic.

Authors:  K J Henrickson; L L Savatski
Journal:  J Clin Microbiol       Date:  1996-03       Impact factor: 5.948

3.  Characterization of a natural mutation in an antigenic site on the fusion protein of measles virus that is involved in neutralization.

Authors:  J Fayolle; B Verrier; R Buckland; T F Wild
Journal:  J Virol       Date:  1999-01       Impact factor: 5.103

4.  Modification of the trypsin-dependent cleavage activation site of the human metapneumovirus fusion protein to be trypsin independent does not increase replication or spread in rodents or nonhuman primates.

Authors:  Stéphane Biacchesi; Quynh N Pham; Mario H Skiadopoulos; Brian R Murphy; Peter L Collins; Ursula J Buchholz
Journal:  J Virol       Date:  2006-06       Impact factor: 5.103

5.  Sequence determination and molecular analysis of two strains of bovine parainfluenza virus type 3 that are attenuated for primates.

Authors:  J E Bailly; J M McAuliffe; M H Skiadopoulos; P L Collins; B R Murphy
Journal:  Virus Genes       Date:  2000       Impact factor: 2.332

6.  Proteolytic cleavage of wild type and mutants of the F protein of human parainfluenza virus type 3 by two subtilisin-like endoproteases, furin and Kex2.

Authors:  D Ortmann; M Ohuchi; H Angliker; E Shaw; W Garten; H D Klenk
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

7.  Inter- and intra-patient sequence diversity among parainfluenza virus-type 1 nucleoprotein genes.

Authors:  V P Dave; S V Hetherington; A Portner; R J Leggiadro; J L Hurwitz
Journal:  Virus Genes       Date:  1997       Impact factor: 2.332

8.  Complete genome sequence and pathogenicity of two swine parainfluenzavirus 3 isolates from pigs in the United States.

Authors:  Dan Qiao; Bruce H Janke; Subbiah Elankumaran
Journal:  J Virol       Date:  2009-11-11       Impact factor: 5.103

Review 9.  Biology of parainfluenza viruses.

Authors:  R Vainionpää; T Hyypiä
Journal:  Clin Microbiol Rev       Date:  1994-04       Impact factor: 26.132

10.  Evaluation of a live attenuated, cold-adapted parainfluenza virus type 3 vaccine in children.

Authors:  R B Belshe; R A Karron; F K Newman; E L Anderson; S L Nugent; M Steinhoff; M L Clements; M H Wilson; S L Hall; E L Tierney
Journal:  J Clin Microbiol       Date:  1992-08       Impact factor: 5.948

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.